Ipca Laboratories upgraded FY27 revenue growth guidance to 14-16 per cent from 12-13 per cent and raised consolidated EBITDA margin guidance to 23 per cent from 22 per cent.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.